SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
PLANO, Texas, May 03, 2017 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to present at the 18th Annual B. Riley Co. Investor Conference in Santa Monica, CA. Management will also be available for one-on-one meetings at the conference.
Event: 18th Annual B. Riley Co. Investor Conference
Format: Presentation and One-on-One Meetings
Date: Wednesday, May 24, 2017
Time: 2:00 pm PT
A webcast of the Company’s presentation will be available on the investor relations section of Nuvectra’s website at www.nuvectramed.com. A webcast replay of the chat will be available for 90 days.
About Nuvectra Corporation
Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, Chief Operating Officer and Chief Financial Officer (214) 474-3102 [email protected] Jennifer Armstrong, Media Relations (214) 474-3110 [email protected] Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 [email protected] Zack Kubow (646) 536-7020 [email protected]
